表紙
市場調查報告書

焦點市場分析:飲食障礙

Market Spotlight: Eating Disorders

出版商 Datamonitor Healthcare 商品編碼 633160
出版日期 內容資訊 英文 36 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:飲食障礙 Market Spotlight: Eating Disorders
出版日期: 2020年07月21日內容資訊: 英文 36 Pages
簡介

全球從10歲到19歲的女性人口飲食障礙的患病人數預測將從2017年的約3560萬人,增加到2026年的3810萬人。

與本報告提供全球飲食障礙的治療藥市場調查,彙整疾病的背景·概要,患病人數的十年預測,已上市藥物與核准趨勢,主要的開發平台概要,授權·資產收購等企業間的主要交易趨勢,主要藥物的銷售額預測,臨床試驗狀況等資料。

概要

主要的要點

疾病的背景

  • 亞型

治療

  • 心理治療
  • 藥物療法

流行病學

已上市藥物

  • 核准趨勢:各國

開發平台藥物

今後主要的活動

授權·資產收購契約

本源專利

商機

臨床試驗環境

  • 贊助商:各狀況
  • 贊助商:不同階段

文獻

附錄

目錄
Product Code: DMKC0190350

This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Worldwide, Datamonitor Healthcare estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10-19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.

In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.

Edgemont's fluoxetine tablets, Eli Lilly's Prozac, and Takeda's Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.

The only industry-sponsored drug in active clinical development for eating disorders is in Phase II. Relamorelin, which targets ghrelin receptor, is the only therapy in active clinical development for eating disorders. It is being tested as a subcutaneous formulation.

The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 8.9 years in the overall psychiatry space.

All of the clinical trials for eating disorders have been in Phase III. The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major European markets.

Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.

Takeda leads industry sponsors with the highest number of Phase III clinical trials for eating disorders, followed by Johnson & Johnson.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Psychotherapy
  • Medications

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Relamorelin for Eating Disorders (June 25, 2019)
  • OPNT001 for Eating Disorders (February 21, 2019)

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10-19 years, 2017-26
  • Figure 2: Overview of pipeline drugs for eating disorders in the US
  • Figure 3: Pipeline drugs for eating disorders, by company
  • Figure 4: Pipeline drugs for eating disorders, by drug type
  • Figure 5: Pipeline drugs for eating disorders, by classification
  • Figure 6: OPNT001 for Eating Disorders (February 21, 2019): Phase II - Bulimia Nervosa (U.K.)
  • Figure 7: Probability of success in the eating disorders pipeline
  • Figure 8: Clinical trials in eating disorders
  • Figure 9: Top 10 drugs for clinical trials in eating disorders
  • Figure 10: Top 10 companies for clinical trials in eating disorders
  • Figure 11: Trial locations in eating disorders
  • Figure 12: Eating disorders trials status
  • Figure 13: Eating disorders trials sponsors, by phase

LIST OF TABLES|

  • Table 1: Worldwide prevalent cases of eating disorders in females aged 10-19 years, 2017-26
  • Table 2: Prevalent cases of eating disorders in females aged 10-19 years in Africa, 2017-26
  • Table 3: Prevalent cases of eating disorders in females aged 10-19 years in Asia, 2017-26
  • Table 4: Prevalent cases of eating disorders in children aged 10-19 years in Latin America and the Caribbean, 2017-26
  • Table 5: Prevalent cases of eating disorders in children aged 10-19 years in Northern America, 2017-26
  • Table 6: Prevalent cases of eating disorders in children aged 10-19 years in Oceania, 2017-26
  • Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017-26
  • Table 8: Marketed drugs for eating disorders
  • Table 9: Pipeline drugs for eating disorders in the US
  • Table 10: Relamorelin for Eating Disorders (June 25, 2019)
  • Table 11: OPNT001 for Eating Disorders (February 21, 2019)
  • Table 12: Historical global sales, by drug ($m), 2015-19
  • Table 13: Forecasted global sales, by drug ($m), 2020-24